Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Tislelizumab + AT in Neoadjuvant TNBC
NCT04914390Phase 2Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Sep 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in triple-negative breast cancer (TNBC), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Pathological Complete Response Rate (ypT0/Tis ypN0). Started Sep 2023; status: recruiting.
02
Drugs
anlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04914390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914390.